LY2422347 + placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sleep Initiation and Maintenance Disorders

Conditions

Sleep Initiation and Maintenance Disorders

Trial Timeline

Nov 1, 2005 → Nov 1, 2006

About LY2422347 + placebo

LY2422347 + placebo is a phase 2 stage product being developed by Eli Lilly for Sleep Initiation and Maintenance Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00259311. Target conditions include Sleep Initiation and Maintenance Disorders.

What happened to similar drugs?

20 of 20 similar drugs in Sleep Initiation and Maintenance Disorders were approved

Approved (20) Terminated (2) Active (0)
Zolpidem MR + EstazolamAstellas PharmaApproved
Zolpidem MR + Zolpidem IRAstellas PharmaApproved
Lemborexant + PlaceboEisaiApproved
Eszopiclone + Placebo controlSumitomo PharmaApproved
Eszopiclone + Fluoxetine + PlaceboSumitomo PharmaApproved
Lunesta + Placebo controlSumitomo PharmaApproved
LunestaSumitomo PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00259311Phase 2Completed

Competing Products

20 competing products in Sleep Initiation and Maintenance Disorders

See all competitors